<DOC>
	<DOCNO>NCT00196989</DOCNO>
	<brief_summary>This Phase 2 dose-ranging study evaluate efficacy , safety tolerability range dose GW677954 compare placebo sixteen week treatment subject T2DM ( Type 2 Diabetes Mellitus ) .</brief_summary>
	<brief_title>Study In People With Type 2 Diabetes</brief_title>
	<detailed_description>A Multicenter , Randomized , Double-Blind , Double-Dummy , Parallel-Group , Placebo-Controlled , Study To Evaluate Efficacy , Safety And Tolerability Of Oral GW677954 Capsules ( 2.5 , 5 , 10 , 15 And 20 Mg Once A Day ) As A Monotherapy ( Diet and/or exercise treat ) Or As An Add-On To Metformin For 16 Weeks Duration In Subjects With Type 2 Diabetes Mellitus</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Inclusion criterion : Subjects T2DM define criterion ADA and/or recognize WHO Expert Committee Diagnosis Classification Diabetes Mellitus [ American Diabetes Association , 2004 ] , least 3 month precede screening ( see Section 15.3 , Appendix 3 : , `` Diagnosis Classification Diabetes Mellitus '' ) . To eligible Randomization trial , subject must satisfy follow glycemic criterion : HbA1c level via central laboratory prescreening visit If HbA1c ≥ 8.0 % ≤ 10.0 % : subject may proceed Randomization ; If HbA1c ≥ 7.8 % &lt; 8.0 % , subject eligible proceed , may retested establish eligibility ( lack thereof ) . If HbA1c level ≥ 8.0 % upon retest , subject eligible proceed ; otherwise withdrawn . If HbA1c &lt; 7.8 % , subject eligible proceed ( retest allow ) . FPG level via central laboratory prescreening visit must &lt; 270 mg/dL ( 15.0 mmol/L ) . FPG may retested within week confirm eligibility ( lack thereof ) . Concurrent T2DM therapy : Diet and/or exercise treat : Must take antidiabetic medication least 2 month prior prescreening visit , OR Metformin monotherapy : Subjects enter study metformin must dose , formulation regimen metformin least 2 month prior prescreening visit , AND TZDs insulin exclude 3 month prior Screening visit subject . Males females 18 70 year age inclusive time Screening . If female , eligible enter participate study : If nonchildbearing potential ( i.e. , physiologically incapable become pregnant ( tubal ligation ) , include female postmenopausal [ &gt; 1 year without menstrual period ] ) ; , If childbearing potential , negative pregnancy test Screening ( serum ) , Randomization ( urine ) : Has male partner sterile prior female subject 's entry study sole sexual partner female subject , Uses doublebarrier method contraception ; condom use cap ( spermicide ) IUDs acceptable , Uses hormonal contraceptive ( oral , depot , patch etc ) double barrier method contraception outline , Abstains sexual intercourse , Is sex partner participate bisexual activity risk pregnancy . Body Mass Index ( BMI ) : ≥25 ≤40 kg/m² weigh least 50 kg Screening . If subject smoker , must able abstain clinic visit . Subject give full write informed consent prior study related procedure perform . Exclusion criterion : Metabolic Disease include : Diagnosis Type 1 diabetes mellitus Uncorrected thyroid dysfunction . ( NOTE : subject hypothyroidism stable dose thyroid replacement therapy least 1 month prior Screening , screen thyroid stimulate hormone ( TSH ) within upper limit normal may participate ) . Significant weight gain loss ( define &gt; 5 % total body weight ) within 3 month prior Screening . Previous use insulin treatment hyperglycemia within 3 month Screening . History recent clinically significant cardiovascular disease include : History ECG evidence prior myocardial infarction within 6 month prior Screening . Current unstable angina history unstable angina past 6 month . Coronary revascularization include percutaneous transluminal coronary angioplasty ( PTCA ) coronary artery bypass graft ( CABG ) surgery either plan occur 6 month prior Screening . Clinically significant arrhythmia valvular heart disease . Congestive heart failure ( CHF ) New York Heart Association ( NYHA ) Class IIIV symptom ( see Section 15.4 , Appendix 4 ) . Blood pressure &gt; 160/100 mmHg rest heart rate &gt; 100 bpm . Note : subject use antihypertensive [ e.g. , beta blocker , angiotensin convert enzyme ( ACE ) inhibitor , angiotensin II antagonist , calcium channel blocker diuretic ] must stable dos 30 day prior Screening trial . Has QTc interval ( Bazett 's ) &gt; 440 msec male &gt; 450 msec female Screening . Clinically significant ECG abnormality , opinion Investigator , may affect interpretation safety data , otherwise , contraindicate participation clinical trial new chemical entity . History chronic pancreatitis . Familial hypercholesterolemia . TGs ≥800 mg/dL ( 8.96 mmol/L ) Screening . Serum creatinine screen &gt; 1.4 mg/dL ( 124 µmol/L ) woman , &gt; 1.5 mg/dL ( 133 µmol/L ) men . Clinically significant anemia define hemoglobin concentration &lt; 12.0 g/dL &lt; 120.0 g/L male &lt; 11.0 g/dL &lt; 110.0 g/L female . History significant comorbid disease ( e.g. , cholelithiasis , gastrointestinal disease , etc . ) would preclude participation study . Documented history hepatobiliary disease include history , positive laboratory result hepatitis ( hepatitis B surface antigen and/or hepatitis C antibody ) Screening , and/or clinically significant hepatic enzyme elevation include : •Any one follow enzymes great 2.5 time upper limit normal ( ULN ) value Screening : Alanine aminotransferase ( ALT ) Aspartate aminotransferase ( AST ) Alkaline phosphatase ( ALP ) Total direct bilirubin &gt; 1.5 time ULN Screening , unless consistent presumed diagnose Gilbert 's disease . History metabolic acidosis , rhabdomyolysis , myalgia , myositis myopathy take statin fibrates . Any subject withdrawn therapy due AEs take PPARγ PPARα/γ dual agonist , either market ( e.g. , troglitazone , rosiglitazone pioglitazone ) current previous clinical investigation . Signs symptom myositis Screening ( upon 1 repeat test ) , and/or creatinine phosphokinase ( CPK ) ≥3.0 time ULN Is currently take take follow medication 3 month prior prescreening visit : Antiobesity agent ( include fat absorption block agent ) St. John 's Wort Warfarin oral anticoagulant ( exclude aspirin nonsteroidal antiinflammatory drug ) Digoxin Oral injectable corticosteroid ( inhale intranasal steroid acceptable ) Use antidiabetic agent ( metformin ) 2 month prior prescreening visit . Use TZDs 3 month prior prescreening visit . Methotrexate , cyclosporine monoclonal antibody ( e.g. , alemtuzumab , gemtuzumab ozogamicin , rituximab , trastuzumab , ibritumomab , tiuxetan ) rheumatoid arthritis psoriasis . Atypical antipsychotic medication [ e.g. , aripiprazole ( Abilify ) , risperidone ( Risperdal ) , clozapine ( Clozaril ) , olanzapine ( Zyprexa ) , quetiapine ( Seroquel ) , ziprasidone ( Geodon ) ] . Antiretroviral drug Use lipid lowering agent within 3 month prior prescreening visit . This include statin , fibrates , ezetimibe ( Zetia ) , niacin bile acid sequestrants . Monoamine oxidase inhibitor History cancer except follow : Basal cell carcinoma superficial squamous cell carcinoma treat local excision . Cervical cancer situ treat definitively 6 month prior screen . Women lactate , pregnant , plan become pregnant . Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate study drug . Known allergy capsule excipients , history drug allergy , , opinion responsible study physician , contradict participation . Hypersensitivity metformin component ( subject enter metformin ) . Has history substance and/or alcohol abuse within past year determine Investigator screen treatment : Unwilling refrain use illicit drug adhere protocolstated restriction participate study . History alcohol abuse define average weekly intake great 21 unit average daily intake great 3 unit ( male ) define average weekly intake great 14 unit average daily intake great 2 unit ( female ) . One unit equivalent halfpint beer 1 measure spirit 1 glass wine . Received treatment new molecular entity ( investigational drug ) previous 4 month participate trial previous 3 month , participate previous study GW677954 . A new molecular entity define compound Phase 3 . ( The washout last dose investigational product previous study first dose investigational product . ) Likely noncompliant , investigator 's opinion , respect protocol relate schedule visit . Subject concomitant medical condition opinion investigator make unsuitable participate study . Subject either immediate family member participate investigator , study coordinator , employee investigator ; member staff conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Efficacy</keyword>
	<keyword>PPARpan</keyword>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Phase IIb</keyword>
	<keyword>Safety</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>GW677954</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Dose-Ranging</keyword>
</DOC>